Author:
Fabi Alessandra,Ferretti Gianluigi,Papaldo Paola,Salesi Nello,Ciccarese Mariangela,Lorusso Vito,Carlini Paolo,Carpino Armando,Mottolese Marcella,Cianciulli Anna Maria,Giannarelli Diana,Sperduti Isabella,Felici Alessandra,Cognetti Francesco
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference40 articles.
1. Perez AT, Domenech GH, Frankel C, Vogel CL (2002) Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest 20(Suppl 2):22–29
2. Gabizon A, Martin F (1994) Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 54(Suppl 4):15–21
3. Gabizon AA (1994) Liposomal anthracyclines. Hematol Oncol Clin North Am 8:431–450
4. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 54(Suppl 4):15–21
5. O’Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–449
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献